© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Shattuck Labs, Inc. (STTK) stock declined over -3.16%, trading at $6.43 on NASDAQ, down from the previous close of $6.64. The stock opened at $6.51, fluctuating between $6.25 and $6.63 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 13, 2026 | 6.63 | 6.63 | 6.25 | 6.43 | 863.44K |
| Jul 10, 2026 | 7.02 | 7.03 | 6.28 | 6.64 | 1.73M |
| Jul 09, 2026 | 6.87 | 7.14 | 6.67 | 7.03 | 643.6K |
| Jul 08, 2026 | 7.25 | 7.50 | 6.88 | 6.88 | 1.03M |
| Jul 07, 2026 | 7.28 | 7.38 | 6.84 | 7.26 | 1.43M |
| Jul 06, 2026 | 7.03 | 7.60 | 6.90 | 7.24 | 1.1M |
| Jul 02, 2026 | 6.50 | 7.06 | 6.45 | 7.05 | 908.79K |
| Jul 01, 2026 | 7.04 | 7.22 | 6.34 | 6.51 | 1.99M |
| Jun 30, 2026 | 6.85 | 7.41 | 6.63 | 6.94 | 1.9M |
| Jun 29, 2026 | 6.33 | 6.88 | 6.17 | 6.85 | 2.04M |
| Jun 26, 2026 | 5.87 | 6.47 | 5.75 | 6.44 | 12.48M |
| Jun 25, 2026 | 6.10 | 6.48 | 5.89 | 5.91 | 1.28M |
| Jun 24, 2026 | 5.39 | 6.18 | 5.26 | 6.01 | 1.36M |
| Jun 23, 2026 | 5.13 | 5.49 | 5.07 | 5.39 | 577.12K |
| Jun 22, 2026 | 5.00 | 5.28 | 5.00 | 5.24 | 673.28K |
| Jun 18, 2026 | 4.89 | 5.08 | 4.73 | 4.95 | 1.22M |
| Jun 17, 2026 | 4.36 | 4.77 | 4.35 | 4.74 | 742.88K |
| Jun 16, 2026 | 4.67 | 4.72 | 4.27 | 4.33 | 642.31K |
| Jun 15, 2026 | 4.97 | 5.10 | 4.61 | 4.63 | 962.91K |
| Jun 12, 2026 | 4.47 | 5.04 | 4.47 | 4.94 | 1.29M |
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
| Employees | 44 |
| Beta | 1.06 |
| Sales or Revenue | $1.66M |
| 5Y Sales Change% | -0.974% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |